PD-1 inhibitors-based second-line therapy for metastatic gastric cancer
BackgroundMetastatic gastric cancer (MGC) patients with progression on first-line treatment still have poor outcomes on chemotherapy. The KEYNOTE-061 study demonstrated that pembrolizumab, a PD-1inhibitor, was not better than paclitaxel as second-line therapy for MGC. Herein, we explored the efficac...
Main Authors: | Miaomiao Gou, Yong Zhang, Zhikuan Wang, Guanghai Dai |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1136437/full |
Similar Items
-
Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
by: P Bohanes, et al.
Published: (2011-08-01) -
Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy
by: Miaomiao Gou, et al.
Published: (2022-09-01) -
Clinical example of enhancing efficacy of paclitaxel by combining it with ramuchirumabin in the second-line chemotherapy of disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2019-06-01) -
Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
by: Caiyun Nie, et al.
Published: (2022-11-01) -
Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population
by: Diana Galos, et al.
Published: (2023-12-01)